Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | PCRX | Common Stock | Options Exercise | $108K | +9.81K | +7.57% | $11.02 | 139K | Feb 28, 2022 | Direct | |
transaction | PCRX | Common Stock | Options Exercise | $208K | +18.8K | +13.52% | $11.02 | 158K | Feb 28, 2022 | Direct | |
transaction | PCRX | Common Stock | Sale | -$1.91M | -28.6K | -18.11% | $66.83 | 130K | Feb 28, 2022 | Direct | F1 |
transaction | PCRX | Common Stock | Options Exercise | $2.13K | +193 | +0.15% | $11.02 | 130K | Mar 1, 2022 | Direct | |
transaction | PCRX | Common Stock | Options Exercise | $12.8K | +1.17K | +0.9% | $11.02 | 131K | Mar 1, 2022 | Direct | |
transaction | PCRX | Common Stock | Sale | -$92.1K | -1.36K | -1.04% | $67.75 | 130K | Mar 1, 2022 | Direct |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | PCRX | Stock Option (Right to Buy) | Options Exercise | $0 | -9.81K | -98.07% | $0.00 | 193 | Feb 28, 2022 | Common Stock | 9.81K | $11.02 | Direct | F2 |
transaction | PCRX | Stock Option (Right to Buy) | Options Exercise | $0 | -18.8K | -94.17% | $0.00 | 1.17K | Feb 28, 2022 | Common Stock | 18.8K | $11.02 | Direct | F3 |
transaction | PCRX | Stock Option (Right to Buy) | Options Exercise | $0 | -193 | -100% | $0.00* | 0 | Mar 1, 2022 | Common Stock | 193 | $11.02 | Direct | F2 |
transaction | PCRX | Stock Option (Right to Buy) | Options Exercise | $0 | -1.17K | -100% | $0.00* | 0 | Mar 1, 2022 | Common Stock | 1.17K | $11.02 | Direct | F3 |
Id | Content |
---|---|
F1 | he price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.750 to $67.155, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
F2 | The stock option vested and became exercisable in twelve equal monthly installments, with the first installment being on May 3, 2012. |
F3 | The option vested and became exercisable as to 25% of the option shares on April 3, 2013 and as to the remaining shares in successive equal monthly installments for the subsequent 36 months. |